PI Perspective 23 -- November 1997
- On The Road Between Euphoria and Failure
- Nearing the end of the second year of the "protease inhibitor era" patients, physicians and treatment activists are anxiously looking for clearer answers about the use of these new drugs. Thanks largely to the media, public expectations have been driven so high that no therapy could live up to the promises made for these drugs.
- Strategies for Protease Inhibitor Failure
- Project Inform’s "Antiviral Strategies" discussion paper previously addressed the question of treatment strategy for people who have already used and "failed" most existing combination therapies.
PI Perspective 22 -- September 1997
- The Coming Sunset on AIDS Funding Programs
- At the heart of all the overheated discussion of recent advances in AIDS therapy lies a simple but profound change in the way we deal with the disease. For the first time, it has become possible (and necessary) to think of treatment as a long-term, planned strategy aimed at getting us through many years, rather than a few months.
- New Federal Guidelines for the Use of Antiretroviral Agents
- Approximately one and a half years after the approval of the first protease inhibitor, the US Department of Health and Human Services has issued its first new set of guidelines for the treatment of HIV disease in several years.
PI Perspective 21 -- March 1997
- Themes . . . The IVth Conference on Human Retroviruses and Opportunistic Infections
- The fourth meeting of the Human Retrovirus Conference in Washington, D.C., in late January brought new evidence that the recent advances in AIDS treatment are producing sustained results.
- A Conference on the Verge of Dysfunction
- The IVth Conference on Human Retroviruses and Opportunistic Infections (HRC) was noted not only for its useful scientific content but also for the intense debate it triggered about the nature, size and makeup of the meeting itself.
- Viral Load and Progression
- The excitement raised by the results from recent protease inhibitor studies have been tempered by the gaps in knowledge on how to best use these therapies as well as concerns about drug resistance.
- ACTG 320: Last of the Body Count Trials?
- In what was hopefully the last trial of its type, ACTG 320 was halted early when one of its treatment regimens proved clearly superior to the other.
- Antiviral Update
- Reports from the IV Conference on Human Retroviruses and Opportunistic Infections in Washington, DC, in January 1997 continued to present the success of 3-drug combinations for the treatment of HIV.
- AZT During Pregnancy
- The NIH recently held an independent panel to assess data from two studies of AZT toxicity to mouse fetuses and whether this new data had implications for AZT use in pregnant women.
- Nelfinavir At Six Months
- Nelfinavir (Viracept) is the newest protease inhibitor, and was approved by the Food and Drug Administration (FDA) in mid-March as long awaited results from a few nelfinavir studies became available.
- Drug Interactions with Nelfinavir
- Some important information on interactions between nelfinavir and other commonly used drugs have recently been made available
This information is designed to support, not replace, the relationship that exists between you and your doctor.©1998. ÆGIS.